Suppr超能文献

代谢性疾病的医学食品:历史、现状和迫切需求。

Medical Foods for Inborn Errors of Metabolism: History, Current Status, and Critical Need.

机构信息

Department of Pediatrics, University of Minnesota, Minneapolis, Minnesota;

National Phenylketonuria Alliance Inc, Eau Claire, Wisconsin.

出版信息

Pediatrics. 2020 Mar;145(3). doi: 10.1542/peds.2019-2261. Epub 2020 Feb 7.

Abstract

Successful intervention for inborn errors of metabolism (IEMs) is a triumph of modern medicine. For many of these conditions, medical foods are the cornerstone of therapy and the only effective interventions preventing disability or death. Medical foods are designed for patients with limited or impaired capacity to ingest, digest, absorb, or metabolize ordinary foods or nutrients, whereby dietary management cannot be achieved by modification of the normal diet alone. In the United States today, access to medical foods is not ensured for many individuals who are affected despite their proven efficacy in the treatment of IEMs, their universal use as the mainstay of IEM management, the endorsement of their use by professional medical organizations, and the obvious desire of families for effective care. Medical foods are not sufficiently covered by many health insurance plans in the United States and, without insurance coverage, many families cannot afford their high cost. In this review, we outline the history of medical foods, define their medical necessity, discuss the barriers to access and reimbursement resulting from the regulatory status of medical foods, and summarize previous efforts to improve access. The Advisory Committee on Heritable Disorders in Newborns and Children asserts that it is time to provide stable and affordable access to the effective management required for optimal outcomes through the life span of patients affected with IEMs. Medical foods as defined by the US Food and Drug Administration should be covered as required medical benefits for persons of all ages diagnosed with an IEM.

摘要

成功干预先天性代谢缺陷(IEMs)是现代医学的一大胜利。对于许多此类疾病,医用食品是治疗的基石,也是预防残疾或死亡的唯一有效干预措施。医用食品是为那些摄入、消化、吸收或代谢普通食物或营养素能力有限或受损的患者设计的,仅通过调整普通饮食无法实现饮食管理。尽管医用食品在治疗 IEMs 方面已被证明有效,已被普遍用作 IEM 管理的主要手段,也得到了专业医疗组织的认可,而且许多家庭显然希望得到有效的治疗,但美国仍有许多受影响的个人无法获得医用食品。在美国,许多健康保险计划都没有充分涵盖医用食品,而且许多家庭由于其高昂的费用而无法负担。在这篇综述中,我们概述了医用食品的历史,定义了其医疗必要性,讨论了由于医用食品的监管地位而导致的准入和报销障碍,并总结了以往为改善准入而做出的努力。新生儿和儿童遗传性疾病咨询委员会断言,现在是时候通过为受 IEM 影响的患者提供终生所需的有效管理,为他们提供稳定且负担得起的医疗服务了。经美国食品和药物管理局定义的医用食品应作为所有年龄段确诊为 IEM 患者的必需医疗福利进行覆盖。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验